AR046672A1 - Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol - Google Patents

Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol

Info

Publication number
AR046672A1
AR046672A1 ARP040104378A ARP040104378A AR046672A1 AR 046672 A1 AR046672 A1 AR 046672A1 AR P040104378 A ARP040104378 A AR P040104378A AR P040104378 A ARP040104378 A AR P040104378A AR 046672 A1 AR046672 A1 AR 046672A1
Authority
AR
Argentina
Prior art keywords
17beta
estra
trien
diol
vinil
Prior art date
Application number
ARP040104378A
Other languages
English (en)
Inventor
Karl-Heinrich Fritzemeier
Christa Hegel-Hartung
Olaf Peters
Ludwig Neyses
Theo Pelzer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR046672A1 publication Critical patent/AR046672A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso de los agonistas de Erbeta 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-flúor-9alfa-vinil-estra-1,3,5(10)-trien-3,16alfa-diol para producir medicamentos para la prevención y/o el tratamiento de enfermedades cardiacas hipertensivas, especialmente para la prevención y/o el tratamiento de una o más de las condiciones seleccionadas del grupo que consiste en (1) hipertensión, (2) hipertrofia cardiaca y (3) deficiencia cardíaca.
ARP040104378A 2003-11-26 2004-11-26 Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol AR046672A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090406 2003-11-26

Publications (1)

Publication Number Publication Date
AR046672A1 true AR046672A1 (es) 2005-12-14

Family

ID=34626396

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104378A AR046672A1 (es) 2003-11-26 2004-11-26 Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol

Country Status (16)

Country Link
US (1) US20050148560A1 (es)
EP (1) EP1689410B1 (es)
JP (1) JP2007512279A (es)
AR (1) AR046672A1 (es)
AT (1) ATE395919T1 (es)
DE (1) DE602004014020D1 (es)
DK (1) DK1689410T3 (es)
ES (1) ES2307064T3 (es)
GT (1) GT200400241A (es)
PA (1) PA8618401A1 (es)
PE (1) PE20050665A1 (es)
PL (1) PL1689410T3 (es)
PT (1) PT1689410E (es)
TW (1) TW200530263A (es)
UY (1) UY28630A1 (es)
WO (1) WO2005051401A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
CA2676066C (en) 2007-01-22 2016-06-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
EP2143432A1 (en) * 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
MXPA02010066A (es) * 2000-04-12 2003-06-04 Schering Ag Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos.
GB2374412A (en) * 2001-04-11 2002-10-16 Karobio Ab Hypertension treatment and assay
DE10226326A1 (de) * 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
US7414043B2 (en) * 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens

Also Published As

Publication number Publication date
EP1689410B1 (en) 2008-05-21
DE602004014020D1 (de) 2008-07-03
DK1689410T3 (da) 2008-09-08
PT1689410E (pt) 2008-08-18
US20050148560A1 (en) 2005-07-07
ES2307064T3 (es) 2008-11-16
WO2005051401A2 (en) 2005-06-09
UY28630A1 (es) 2005-06-30
PE20050665A1 (es) 2005-11-02
TW200530263A (en) 2005-09-16
PA8618401A1 (es) 2005-08-04
GT200400241A (es) 2005-10-31
ATE395919T1 (de) 2008-06-15
JP2007512279A (ja) 2007-05-17
EP1689410A2 (en) 2006-08-16
PL1689410T3 (pl) 2008-10-31
WO2005051401A3 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
AR045016A1 (es) Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
CY1105299T1 (el) Χρηση των επιλεκτικων αγωνιστων του υποδοχεα 4 (ep4) προσταγλανδινης (pge2) για τη θepαπεια της οξειας και χρονιας νεφρικης ανεπαρκειας
CY1105080T1 (el) Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY2607B2 (en) Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists
NO20030374D0 (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
ECSP066411A (es) Tienopirazoles
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
CY1108808T1 (el) Ενωσεις μοτιλιδης
AR059203A1 (es) Composiciones para uso vaginal
AR046672A1 (es) Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
NO20062699L (no) Smelteblandingsdispergeringer
CL2007002392A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hiperplasia prostatica benigna, enfermedad de barrett, asma, enfermedad de crohn, reparacion de musculo esqueletico y tendon, colitis ulcerosa y leishmaniasis.
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
UY29109A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
BR0307903A (pt) derivados de arilsulfona
CL2004000877A1 (es) Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu

Legal Events

Date Code Title Description
FB Suspension of granting procedure